Compare Sana Biotechnology Inc (SANA) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Under Armour Inc Class A — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Under Armour Inc Class A trades at $5.07 (market cap $2.15B). The key difference: Under Armour Inc Class A is far larger — about 2.1× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| SANA | UAA | |
|---|---|---|
Market Cap | $1.03B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $8.14 |
52-Week Low | $2.68 | $4.17 |
Enterprise Value | $946.04M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Under Armour (UAA) trades at $5.06, down 3.62% amid bearish technical signals and negative cash flow. The company reported Q2 2026 EPS of $0.05, beating expectations, but faces revenue declines and a net loss of $201 million in 2025. Analyst consensus is mixed with 27% buy ratings and a $6.67 price target, while technical indicators show resistance at $5 with RSI neutral but ADX signaling strong bearish momentum.
UAA's outlook is challenged by weakening revenue and negative profitability, though cost controls and international growth offer some support. Investment opportunity exists if margin improvements translate to sustained earnings, but risks include persistent North America softness and high debt levels. The stock trades near analyst low targets, suggesting limited upside without operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
